Safety and Efficacy of Seroquel in First Episode Schizophrenia

Study identifier:BU-5077-0011

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Safety and efficacy of Seroquel in first episode schizophrenia

Medical condition

schizophrenia

Phase

Phase 4

Healthy volunteers

Study drug

Seroquel and Risperidone

Sex

All

Actual Enrollment

Study type

Interventional

Age

18 Years - 35 Years

Date

Study Start Date: 01 May 2002

Primary Completion Date: -

Study Completion Date: 01 Jun 2006

Study design

Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

Location

Research Site

London, United Kingdom

Arms	Assigned Interventions

"There is no result for the study"

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=1616&filename=CSR-BU-5077-0011.pdf
Download
CSR-BU-5077-0011.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca UK Information

+44 (0)1625 582828

Investigators

Principal Investigator

AstraZeneca Seroquel Medical Science Director

AstraZenenca